These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6979819)

  • 21. Substrate-dependent modulation of the mechanism of factor XIa inhibition.
    Pedicord DL; Seiffert D; Blat Y
    Biochemistry; 2004 Sep; 43(37):11883-8. PubMed ID: 15362874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
    Holmer E; Kurachi K; Söderström G
    Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
    Olson ST; Sheffer R; Francis AM
    Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
    Donaldson VH; Harrison RA
    Blood; 1982 Jul; 60(1):121-9. PubMed ID: 6211203
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins.
    Mauron T; Lämmle B; Wuillemin WA
    Thromb Haemost; 1998 Jul; 80(1):82-6. PubMed ID: 9684790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
    Schapira M; Scott CF; Colman RW
    Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.
    Meijers JC; Kanters DH; Vlooswijk RA; van Erp HE; Hessing M; Bouma BN
    Biochemistry; 1988 Jun; 27(12):4231-7. PubMed ID: 2844223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor IX activation by factor XIa proceeds without release of a free intermediate.
    Wolberg AS; Morris DP; Stafford DW
    Biochemistry; 1997 Apr; 36(14):4074-9. PubMed ID: 9100000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parallel procoagulant and anticoagulant pathways for high molecular weight kininogen coagulant function.
    Olson ST; Sheffer R; Shore JD
    Agents Actions Suppl; 1992; 38 ( Pt 1)():241-8. PubMed ID: 1466276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor.
    Silverberg M; Longo J; Kaplan AP
    J Biol Chem; 1986 Nov; 261(32):14965-8. PubMed ID: 3639874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2.
    Scandura JM; Zhang Y; Van Nostrand WE; Walsh PN
    Biochemistry; 1997 Jan; 36(2):412-20. PubMed ID: 9003194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured.
    Briseid K; Hoem NO; Johannesen S; Haug K
    Thromb Res; 1995 May; 78(3):239-50. PubMed ID: 7631304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human blood coagulation factor XIa by C-1 inhibitor.
    Meijers JC; Vlooswijk RA; Bouma BN
    Biochemistry; 1988 Feb; 27(3):959-63. PubMed ID: 3259145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small synthetic peptides with affinity for proteases in coagulation and fibrinolysis: an overview.
    Claeson G; Aurell L
    Ann N Y Acad Sci; 1981; 370():798-811. PubMed ID: 6455958
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of kininogen on the activity of human blood serum kininogenase system].
    Datsenko VL; Iarovaia GA; Golosova NA; Lebedeva NV; Orekhovich VN
    Biokhimiia; 1977 Feb; 42(2):283-6. PubMed ID: 856307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen.
    von dem Borne PA; Koppelman SJ; Bouma BN; Meijers JC
    Thromb Haemost; 1994 Sep; 72(3):397-402. PubMed ID: 7855791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine monoclonal antibodies to human factor XI.
    Nishikado H; Komiyama Y; Masuda M; Egawa H; Murata K
    Thromb Res; 1986 Apr; 42(2):225-34. PubMed ID: 3487138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
    Scott CF; Carrell RW; Glaser CB; Kueppers F; Lewis JH; Colman RW
    J Clin Invest; 1986 Feb; 77(2):631-4. PubMed ID: 3484755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity.
    Schiffman S; Mannhalter C; Tyner KD
    J Biol Chem; 1980 Jul; 255(13):6433-8. PubMed ID: 6901530
    [No Abstract]   [Full Text] [Related]  

  • 40. Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.
    Walsh PN; Bradford H; Sinha D; Piperno JR; Tuszynski GP
    J Clin Invest; 1984 May; 73(5):1392-9. PubMed ID: 6609171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.